Lanean...
Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer
Human epidermal growth factor receptor (HER2) negative metastatic breast cancer (BC) accounts for 73% of BC. The molecular analysis of this disease is essential for potential options for targeted therapy. Several promising clinical strategies are being evaluated which includes endocrine therapy, mod...
Gorde:
| Argitaratua izan da: | Int J Biol Sci |
|---|---|
| Egile Nagusiak: | , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Ivyspring International Publisher
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6535782/ https://ncbi.nlm.nih.gov/pubmed/31182917 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/ijbs.30721 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|